Despite the primary failure, the company noted that fasedienol maintained a safety and tolerability profile consistent with earlier placebo-controlled trials. A post-hoc analysis revealed a statistically significant improvement in a specific subset of patients—those suffering from very severe social anxiety—offering a slim margin of encouragement for the development team.

Vistagen now plans to pivot its strategy, shifting away from targeting acute symptom relief toward a broader registrational pathway for long-term anxiety management. Management intends to consult with the Food and Drug Administration regarding a future Phase 3 trial, which would utilize the Liebowitz Social Anxiety Scale as the definitive primary endpoint to measure therapeutic success.